Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05477563
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2022-07-26
Brief Title:
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Beta-Thalassemia |
| Thalassemia |
| Hematologic Diseases |
| Genetic Diseases Inborn |
| Hemoglobinopathies |
| Sickle Cell Anemia |
| Sickle Cell Disease |
Keywords: